We are live on ! Find out more
FHTX icon

Foghorn Therapeutics

61 hedge funds and large institutions have $135M invested in Foghorn Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 15 increasing their positions, 20 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

3% more funds holding

Funds holding: 5961 (+2)

0.34% more ownership

Funds ownership: 63.98%64.32% (+0.34%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

25% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 20

29% less capital invested

Capital invested by funds: $188M → $135M (-$53.8M)

Holders
61
Holders Change
+2
Holders Change %
+3.39%
% of All Funds
0.97%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
3
Increased
15
Reduced
20
Closed
1
Calls
$2K
Puts
Net Calls
+$2K
Net Calls Change
-$288K

FHTX Hedge Fund Activity: Q3 2023 in Review

61 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2023, worth a combined $135M — down 29% from $188M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new FHTX positions and 1 closed out — a net gain of 2 holders — while 15 added to existing stakes and 20 trimmed.

The largest buyer was Raymond James & Associates, adding an estimated $1.81M. The largest seller was BlackRock, cutting an estimated $491K.

  • 61 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2023, up from 59 in Q2 2023.
  • Funds reported $135M of Foghorn Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
  • 3 funds opened new Foghorn Therapeutics positions in Q3 2023 and 1 closed out, a net change of +2 holders.
  • The largest Foghorn Therapeutics buyer in Q3 2023 was Raymond James & Associates, an estimated $1.81M added.
  • The largest Foghorn Therapeutics seller in Q3 2023 was BlackRock, an estimated $491K sold.

Based on aggregated 13F filings for Q3 2023.